Close
ACHEMA MIDDLE EAST 2026
5th LNP Formulation & Process Development Summit

Research & Development

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®

Research & Development
Studies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD studied compared to tiotropium,...

AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers

Research & Development
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene...

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

Research & Development
Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015...

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

Research & Development
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used...

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

Research & Development
AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an...

Immuno-oncology: an update on progress at the European Cancer Congress

Research & Development
Within the rapidly evolving world of cancer treatment and the excitement surrounding immuno-oncology, it is more important than ever to have a strategic approach...

AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)

Research & Development
AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research underpinning its scientific leadership...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

Whitepapers 0
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

Whitepapers 0
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Whitepapers 0
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

About us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

Resources

Advertise

Subscribe

Copyright © Value Media Group 2026. All rights reserved.